<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04391985</url>
  </required_header>
  <id_info>
    <org_study_id>Qu-RBV</org_study_id>
    <nct_id>NCT04391985</nct_id>
  </id_info>
  <brief_title>Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients</brief_title>
  <official_title>Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      enrolled participants were treated orally with SOF plus a fixed dose combination of OBV/PTV/r
      plus RBV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled participants were treated orally with SOF plus a fixed dose combination of
      Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir plus Ribavirin (OBV/PTV/r plus RBV), which was
      administered orally based on the participants' tolerability. The primary end point was a
      sustained virological response (HCV RNA level &lt; 15 IU/ mL), observed 12 weeks after the end
      of the treatment (SVR12).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">October 31, 2017</completion_date>
  <primary_completion_date type="Actual">October 31, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm</measure>
    <time_frame>12 weeks after last dose</time_frame>
    <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) level &lt; 15 IU/ml 12 weeks after the last dose of drugs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events in Each Treatment Arm</measure>
    <time_frame>Screening up to 12 weeks after last dose]</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant clinical investigation after administering a pharmaceutical drugs Serious adverse event (SAE) is an event that results in death, life-threatening, requires hospitalization, or significant disability/incapacity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Viral relapse</measure>
    <time_frame>Up to 12 weeks after last dose</time_frame>
    <description>Viral relapse was HCV RNA level undetectable at End of Treatment (EOT) (â‰¤ 15 IU/ml), but detectable HCV RNA ( &gt; 15 IU/ml) levels 12 weeks after planned EOT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Chronic Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>Cirrhotic Participants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The experienced participants(113 participants) who failed prior DAA treatments. They were allocated to cirrhotic (30 participants) and treated for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-cirrhotic Participants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The experienced non-cirrhotic participants(83 participants) who failed prior DAA treatments. They were treated for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF plus (OBV/PTV/r) plus RBV</intervention_name>
    <description>They were given SOF in a dose of 400 mg/day, and a fixed dose combination of OBV (25 mg), PTV (150 mg), and r (100 mg) taken with food once daily. RBV was supplied in 200 mg capsules, and the recommended dose was 600 mg/ day to reach 1200 mg/day based on patient's body weight and tolerability.</description>
    <arm_group_label>Cirrhotic Participants</arm_group_label>
    <arm_group_label>Non-cirrhotic Participants</arm_group_label>
    <other_name>Paritaprevir (ABT-450) is inhibitor of the NS3-4A serine protease</other_name>
    <other_name>Sovaldi is a trade name of sofosbuvir</other_name>
    <other_name>Ombitasvir (ABT 267) is an NS5A inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The experienced participants who were treated previously with (SOF/DCV) , (SOF/SMV),
             (SOF/RBV), or (SOF/pegINF/RBV).

          -  The presence of compensated liver cirrhosis was documented by ultrasonographic
             examination, liver biopsy, results of Fibroscan or FIB-4 score, and laboratory
             markers, like FIB-4 &gt; 3.25 (advanced fibrosis or cirrhosis), albumin &lt; 3.5, total
             bilirubin &gt; 1.2, and also confirmed by clinical characteristics such as lower limb
             edema, splenomegaly, esophageal varices.

        Exclusion Criteria:

          -  liver disease of non-HCV GT4 etiology, coinfection with hepatitis B or HIV

          -  poorly controlled diabetes (HbA1C &gt; 8)

          -  participants, hepatocellular carcinoma, a history of extrahepatic malignancy in the 5
             years prior to the study

          -  renal failure

          -  evidence of hepatic decompensation

          -  blood picture abnormalities such as anemia (hemoglobin concentration of &lt; 10 g/dL)

          -  thrombocytopenia (platelets count &lt; 50,000 cells/mm3).

          -  major severe illness such as congestive heart failure and respiratory failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beni-Suef University</name>
      <address>
        <city>Beni-Suef</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>https://link.springer.com/article/10.1007/s10620-018-5005-8</url>
    <description>This link clarify the retreatment efficacy and safety of the SOF with OBV/PTV/r + RBV, for chronic HCV GT4-experienced patients who failed treatment with DAA-based regimens.</description>
  </link>
  <results_reference>
    <citation>Abdel-Moneim A, Aboud A, Abdel-Gabbar M, Zanaty M, Ramadan M. Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients. Dig Dis Sci. 2018 May;63(5):1341-1347. doi: 10.1007/s10620-018-5005-8. Epub 2018 Mar 15.</citation>
    <PMID>29546644</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Mohammed Abdel-Gabbar, Ph.D</investigator_full_name>
    <investigator_title>Associate Prof</investigator_title>
  </responsible_party>
  <keyword>Sofosbuvir</keyword>
  <keyword>Ombitasvir</keyword>
  <keyword>Paritaprevir</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Ritonavir</keyword>
  <keyword>HCV GT 4</keyword>
  <keyword>Experienced Egyptian Patients</keyword>
  <keyword>Cirrhotic</keyword>
  <keyword>Non-Cirrhotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

